IFNL1 and Splenomegaly: Starting at 5 days post-hIL-2 injection, HDIL2-treated HIS mice showed marked splenomegaly, nephrotoxicity, and pulmonary edema (Fig. 1c, d); these pathological changes have been previously reported in humans treated with high doses of IL-29.